Gene Silencing, Gene Therapy and Licensing - Clinical Research Informer

uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS

Pharmaceutical Technology

JANUARY 31, 2023

Gene therapy company uniQure has entered into a global licensing agreement with Apic Bio for APB-102 to treat patients with amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1). APB-102 is designed to be a one-time, intrathecally administered gene therapy for ALS patients.

Gene Therapy

Gene Therapy Licensing Licensing Gene

Novartis keeps a close eye on gene therapy with Vedere Bio buy

pharmaphorum

OCTOBER 29, 2020

Already a major player in gene therapy, Novartis has swooped on US startup Vedere Bio in a $280 million deal that builds its position in inherited eye diseases that can lead to blindness. Novartis’ big move in the gene therapy market came when it bought AveXis for $8.7

Gene Therapy

Gene Therapy Gene Gene Silencing Protein

Clinical Research Informer

uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS

Novartis keeps a close eye on gene therapy with Vedere Bio buy

Webinars

Stay Connected